| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA922: Daridorexant for treating long-term insomnia |
|
Medicine details |
|
| Medicine name | daridorexant (Quviviq®) |
| Formulation | 25 mg, 50 mg oral formulation |
| Reference number | 4484 |
| Indication | Treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning. |
| Company | Idorsia Pharmaceuticals Ltd |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/03/2022 |
| NICE guidance | |